ADMA Biologics Accepted to the Plasma Protein Therapeutics Association

- November 4th, 2019

ADMA Biologics will be a member of the Plasma Protein Therapeutics Association as a North America member effective January 1, 2020.

ADMA Biologics (NASDAQ:ADMA) has announced it has been accepted to the Plasma Protein Therapeutics Association (PPTA) effective January 1, 2020.

As quoted in the press release:

  Adam Grossman, President and CEO of ADMA, will join the PPTA North America Board of Directors.

“I am honored that ADMA has been accepted to the PPTA and to be joining PPTA’s North America Board of Directors.  I look forward to serving alongside some of the nation’s most prestigious leaders in the field of immunoglobulins and plasma proteins,” stated Mr. Grossman.  “Given ADMA’s fractionation plant turnaround and my industry experience, we bring a deep understanding of the many unique challenges our industry currently faces and I believe we can make important contributions with the ultimate goal of efficiently bringing plasma-derived products to the patients who need them.”

“Adam brings more than two decades of leadership experience in the field of plasma proteins to PPTA, and we’re thrilled to welcome him to the team,” said Amy Efantis, PPTA’s President and CEO.  “His strategic insight and operational expertise in the North American market will be invaluable as we pursue our mission to advance the plasma protein therapeutics industry to meet the needs of a global population depending on the critical, life-saving medicines produced by PPTA members.”

Click here to read the full press release.

Is the biotech market the perfect mesh between the technology and pharmaceutical market?

 
Read our FREE outlook report below!
 

Get the latest Biotech Investing stock information

Get the latest information about companies associated with Biotech Investing Delivered directly to your inbox.

Biotech Investing

Select All
Select None

Leave a Reply

Your email address will not be published. Required fields are marked *